Medication adherence and relapse in recent-onset psychosis

American Journal of Psychiatry

Volumn 168, Issue 3, 2011, Pages 240-242

  Robinson, Delbert G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

DRUG EFFICACY; DRUG FORMULATION; EDITORIAL; HEALTH CARE PLANNING; MAINTENANCE THERAPY; MONOTHERAPY; ONSET AGE; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RELAPSE; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; MEDICATION ADHERENCE; PSYCHOTIC DISORDERS; RECURRENCE;

EID: 79952723363     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.10121736     Document Type: Editorial

References (11)

1. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168:286-292
2. Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241-247 (Pubitemid 29125132)
3. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158:1835-1842 (Pubitemid 33054776)
4. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D: Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68:654-661 (Pubitemid 46841847)
5. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J: Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210-213 (Pubitemid 351419182)
6. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM: Long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial RCT adherence outcomes. J Clin Psychiatry 2009; 79:1397-1406
7. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J: Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39:70-73 (Pubitemid 12163378)
8. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148:120-127 (Pubitemid 16158512)
9. Scottish Schizophrenia Research Group: The Scottish First Episode Schizophrenia Study, VII: two-year follow-up. Acta Psychiatr Scand 1989; 80:597-602
10. Hogarty GE, Ulrich RF: The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998; 32:243-250 (Pubitemid 28408287)
11. Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, Tso S, Pang EP, Chan KT, Wong YC, Mo FY, Chan KP, Yao TJ, Hung SF, Honer WG: Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomized controlled trial. BMJ 2010; 341:c4024